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Feline rhinotracheitis virus (FRV) is an important upper respiratory tract pathogen of cats. FRV is a member of the
subfamily Alphaherpesvirinae and is designated feline herpesvirus-1 (FHV-1). Besides upper respiratory clinical signs, FHV-
1 may cause generalized infections in neonates or abortions in pregnant queens. Recently we described a recombinant
FHV-1 strain with a deletion in the genes for glycoproteins gI and gE (FHVb-galgIgED) and reported that cats vaccinated
subcutaneously with high doses of the recombinant FHV-1 strain responded with only mild clinical signs and developed
strong immunity against subsequent virulent virus challenge. Here we compare the intranasal and subcutaneous routes of
administration of this strain and assess its ability to induce protective immunity and prevent virus shedding after challenge.
Cats vaccinated subcutaneously or intranasally with high doses of the recombinant FHV-1 strain responded with only mild
clinical signs and developed strong immunity against subsequent virulent virus challenge. This was especially evident when
the mutant vaccine was administered oronasally. In contrast, intranasal administration of two other FHV-1 isolates induced
severe clinical signs in cats. We conclude from testing this FHV-1 mutant in the natural host that deletion of gE and a
portion of gI genes strongly reduces viral virulence but that immunogenicity is maintained. q 1996 Academic Press, Inc.
INTRODUCTION Johnson, 1993; York et al., 1994; Fruh et al., 1995; Hill et
al., 1995).
Virulence of the alphaherpesviruses is complex (Fawl At least 11 glycoproteins are encoded in the genome
and Roizman, 1994). At least five genes known to contrib- of HSV-1 (Roizman and Sears, 1993). A subset of these is
ute to virulence are conserved between alphaherpesvi- essential for growth in tissue cultures of undifferentiated
ruses of veterinary and medical importance and include cells (Balan et al., 1994). Suggestive of their importance
ICP34.5 of human herpesvirus-1 (HSV-1), glycoprotein gE, in vivo, the sequences and structures of the ‘‘nonessen-
glycoprotein gC, thymidine kinase, and UL21 of HSV-1 tial’’ herpesvirus glycoproteins are conserved among
(Chou et al., 1990; Rajcani, 1992; Thompson et al., 1983; alphaherpesviruses of many animal species (Spatz et al.,
van Engelenburg et al., 1994; Willemse et al., 1994; Klupp 1994; Audonnet et al., 1990). Recently we reported the
et al., 1995; Nunberg et al., 1989). Deletion of any of these construction of a feline herpesvirus-1 (FHV-1) recombi-
genes from the genome significantly reduces virulence. nant that specifically lacked part of the unessential glyco-
Deletions of several of them in combinations have pro- protein gI gene and both the 5*-transcriptional control
duced pseudorabies virus (PRV) strains with an even region and 5*-coding region of the unessential glycopro-
greater reduction in virulence (Mettenleiter, 1991). tein gE gene (Sussman et al., 1995). At the molecular
Alphaherpesviruses also have immunoevasive proper- level, a complex composed of glycoproteins gI and gE
ties that enable them to bypass host defense systems,
is required for proper sorting of the varicella-zoster (VZV)
both during the acute phase of infection and during la-
virion in the trans-Golgi network (Zhu et al., 1995). In
tency (Banks and Rouse, 1991; Fitzpatrick and Bielefeldt-
tissue culture glycoproteins, gI and gE are phosphopro-
Ohmann, 1991). Not only does HSV-1 appear to disable
teins required for cell to cell spread and syncytium forma-immunoresponsive cells, such as the natural killer T-
tion during VZV, PRV, FHV-1, and HSV-1 infections (Yaolymphocytes, it is also able to prevent the presentation
and Grose, 1994; Zsak et al., 1992; Sussman et al., 1995;of viral peptides via class I MHC antigens by jamming
Dingwell et al., 1994, 1995). Neither gI nor gE, however,transporter activator proteins required for antigen pre-
is required for growth in tissue culture (Jacobs, 1994).sentation to the cell-mediated immune system (York and
Phenotypically, alphaherpesvirus strains with deletions
in the gE gene or in both the gI and gE genes produce
very small plaques in vitro (Jacobs, 1994; Sussman et al.,1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (517) 353-4426. E-mail: Maes@AHDLMS.CVM.MSU.EDU. 1995; Zuckerman et al., 1988; Yao and Grose, 1994; Zsak
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et al., 1992; Dingwell et al., 1994). In vivo, glycoproteins galgIgED is most effective as a vaccine strain when
administered oronasally. Furthermore, in contrast to thegE and gI of PRV, HSV-1, HSV-2, and VZV are essential
for the spread of infection throughout the host nervous virulent parent strain (FHV-1SA) and a representative
USDA licensed FHV-1 vaccine strain (FHV-1CV), adminis-system, which is ultimately the cause of neurovirulence
(Dingwell et al., 1995; Kritas et al., 1994; Mulder et al., tration of FHVb-galgIgED via the oronasal route was
found to produce only mild clinical symptoms, clearly1994; Enquist, 1994; Enquist et al., 1994).
Members of the family Felidae are the only known indicating that glycoproteins gI and gE of FHV-1 are nec-
essary for the induction of viral virulence associated withhosts for FHV-1 (Povey, 1979; Lincumpao et al., 1991;
Evermann et al., 1982). The widespread contagion of FHV-1 infection of cats.
FHV-1 contributes to 25 to 40% of upper respiratory infec-
tions in cats (Gaskell, 1993; Ellis, 1981). Morbidity may MATERIALS AND METHODS
approach 100% in young animals with substantial mortal-
Catsity among kittens and neonates (Crandell and Maurer,
1958; Spradbow et al., 1971; Shields and Gastin, 1977). Thirty male and 25 female specific-pathogen-free cats
Acute primary FHV-1 infections are characterized by cyto- were used (Harlan Sprague–Dawley, Madison, WI). Cats
pathic viral replication in the upper respiratory tract re- were 10–12 weeks old at the time of initial immunization.
sulting in clinical signs of sneezing, conjunctivitis, ocular Cats were housed in individual cages in rooms with con-
and nasal discharge, fever, depression, and anorexia trolled temperature, humidity, and lighting. They were fed
(Crandell et al., 1961; Povey, 1979). Keratitis, abortion, a combination of dry and moist diets. Each group of cats
and encephalitis have also been associated with FHV-1 was housed in a separate containment (Biocontainment
infections (Bistner et al., 1971). Lifelong latent infection Level-2) room. All cats were acclimated for 7 days before
following acute upper respiratory disease is the rule, and virus exposure. Animal studies were reviewed and ap-
reactivated latent virus is likely to play an important role proved by the Animal Use Committee at Michigan State
in FHV-1 perpetuation and spread (Gaskell and Povey, University.
1979b; Crandell, 1971).
Several FHV-1 strains have been licensed by the U.S. Cell culture and virus strains
Department of Agriculture (USDA) as modified live vac-
cines for feline rhinotracheitis. Many of these are admin- Crandell Reese feline kidney cells (CRFK) and feline
tracheal cells, obtained from the American Type Cultureistered via an unnatural route of infection. Although aviru-
lent when administered subcutaneously or intramuscu- Collection (CCL 94 and CRL 6165, respectively), were
grown in 11 Dulbecco’s modified Eagle’s medium, sup-larly to cats, some licensed FHV-1 vaccines are virulent
when administered oronasally (Povey and Wilson, 1978). plemented with 10% heat-inactivated fetal bovine serum,
100 units/ml streptomycin, and 100 units/ml penicillinIt has been suggested that FHV-1 is not virulent when
administered intramuscularly because it does not repli- (BRL-Life Sciences, Gaithersburg, MD). FHV-1MSU is a
low-passage field strain originally isolated in the Virologycate as efficiently at the cat’s normal core body tempera-
ture as it does at cooler sites in the upper respiratory Section of the Animal Health Diagnostic Laboratory at
Michigan State University (R. K. Maes, unpublished data).tract (Pedersen and Hawkins, 1995). All currently avail-
able vaccines prevent or reduce the severity of clinical FHV-1SA is the virulent parent strain of FHVb-galgIgED
(Sussman et al., 1995). It is a low-passage field isolatesigns after exposure to virulent virus. However, none of
them protect against reinfection with a virulent strain (Dr. D. Hines, personal communication). Prior to use in
this study to ensure that its virulence was not affected(Cocker et al., 1983). Since reactivation of latent FHV-1
is common, vaccinated or recovered cats may act as by repeated passage in CRFK cells, FHV-1SA was pas-
saged 12 times, in parallel to FHVb-galgIgED (Sussmanasymptomatic carriers and perpetuate the spread of viru-
lent virus (Gaskel and Povey, 1982). et al., 1995). FHVb-galgIgED is a recombinant strain de-
rived from FHV-1SA containing a single targeted deletionWe have previously reported a portion of our data
showing that cats inoculated subcutaneously with FHVb- in the gI and gE genes and used from a frozen stock
(106.8 TCID50/ml; Sussman et al., 1995). FHV-1CV is agalgIgED are protected from development of clinical
signs following challenge with a virulent FHV-1 strain representative commercially available subcutaneously
administered FHV-1 vaccine that was passaged 2 times(Sussman et al., 1995). However, vaccination with the
recombinant strain by the subcutaneous route did not prior to use in this study and stored as a frozen stock.
FVR-SGE is the virulent challenge strain specified for useprotect cats as well as vaccination with the virulent par-
ent or another FHV-1 vaccine strain. Here we further in the USDA protocol for scoring feline viral rhinotra-
cheitis (FVR) in cats following virulent challenge. It wascharacterize the immunogenicity and safety of FHVb-gal-
gIgED administered via either the subcutaneous or the supplied by the USDA, National Veterinary Services Lab-
oratory (Ames, IA) as a frozen stock (107.8 TCID50/ml; U.S.oronasal route. Our data provide evidence that FHVb-
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Dept. of Agriculture, 1985). Virus titers were calculated (Sussman et al., 1995). Oropharyngeal and nasal secre-
tions were collected and processed as described aboveby the method of Ka¨rber (1931).
immediately prior to and at 3, 7, 10, and 12 days after
Parent strain selection immunization. Venous blood samples were collected im-
mediately prior to and at 21 and 42 days after initial
Fifteen kittens were randomized into two experimental
immunization. Forty-two days after initial immunization,
groups of six cats each and one unchallenged control
nonimmunized control cats and cats inoculated with
group of three cats. Prior to inoculation, cats were se-
FHVb-galgIgED were oronasally challenged with 105
dated with ketamine hydrochloride (10 mg/kg) and ace-
TCID50 of FVR-SGE. After virulent challenge, all cats werepromazine maleate (0.1 mg/kg). Each experimental group
examined daily and scored for clinical signs for 14 days
was inoculated oronasally with 104 TCID50 of either FHV- (Sussman et al., 1995). Oropharyngeal and nasal secre-
1MSU or FHV-1SA. After inoculation, all cats were exam-
tions were collected immediately prior to and at 2, 4, 7,
ined daily and scored for clinical signs for 14 days as
9, 11, and 14 days after challenge.
previously described (Sussman et al., 1995). Venous
blood samples were collected immediately prior to immu- Virus isolation test
nization and at 2-day intervals after the inoculation. Se-
For virus isolation, virus was extracted from swabs inrum was prepared from the samples and stored at 0707
1 ml 11 EMEM and a portion (100 ml) was used to inocu-prior to performing the virus neutralization tests.
late wells of plastic 24-well plates containing CRFK cell
monolayers. The inoculated cells were examined dailySafety and efficacy studies
for 5 days for evidence of typical FHV-1 CPE.
Subcutaneous inoculation. Trials to determine the
Virus neutralization testsafety and efficacy of FHVb-galgIgED were previously
described (Sussman et al., 1995). A third experimental Serum from immunized cats was analyzed for the pres-
group of five randomly chosen specific-pathogen-free ence of virus neutralizing (VN) antibodies by a modified
cats, not previously described, was also immunized sub- microtiter neutralization assay (Spatz et al., 1994). Heat-
cutaneously with 107 TCID50 of FHV-1CV. As previously inactivated (567 for 30 min) serum was used to make a
described, these immunized cats were examined daily twofold dilution series. Approximately 100 TCID50 of FHV-
for 14 days, scored for clinical signs, and reinoculated 1 C-27 was added to each serial dilution. Virus–serum
with FHV-1CV 21 days after initial immunization (Suss- mixtures in a total of 100 ml EMEM were incubated in
man et al., 1995). Venous blood samples were collected 5% CO2 at 377 for 1 hr, 1.5 1 104 CRFK cells in 100
from cats in every group immediately prior to immuniza- ml were added to each well, and the incubation was
tion, prior to reinoculation (21 days), and 43 days after continued. VN titers are expressed as the log2 of recipro-
the initial immunization. Serum was prepared from the cal of the highest serum dilution resulting in complete
samples and stored at 0707 prior to performing the virus inhibition of cytopathic effect.
neutralization test. Oropharyngeal and nasal secretions
were collected from each cat with sterile rayon-tipped RESULTS
swabs (minitip culturette, Becton–Dickinson) immedi-
Characterization of parent strain FHV-1SA
ately prior to and at 3, 7, 9, and 11 days after initial
Two FHV-1 field isolates, FHV-1MSU and FHV-1SA,immunization. Swabs were stored briefly at 47 until pro-
were evaluated for virulence and immunogenicity. Al-cessed for detection of virus shedding. Forty-two days
though both of these strains were virulent in cats, FHV-after initial immunization, the cats were oronasally chal-
1MSU induced significantly more severe clinical signslenged with 106 TCID50 of FVR-SGE. After virulent chal-
than FHV-1SA (Table 1; Kruskal–Wallis Test, P  0.02;lenge, all cats were examined daily and scored for clini-
Brownlee, 1965). However, there was no significant dif-cal signs for 14 days (Sussman et al., 1995). Oropharyn-
ference in the humoral response of these two strains asgeal and nasal secretions were collected from each cat
detected by the virus neutralization test (Table 1). FHV-3, 6, 9, and 13 days after challenge and stored at 47 prior
1SA was chosen as the parent strain for the constructionto being processed for detection of virus shedding.
of FHVb-galgIgED because it was the less virulent ofOronasal inoculation. Thirty kittens were randomized
the two strains and was equally immunogenic to FHV-into six groups of five cats each. Cats were sedated and
1MSU, based upon VN titers (Sussman et al., 1995).each group was immunized oronasally with 103 TCID50 ,
104 TCID50 , or 10
5 TCID50 of FHVb-galgIgED or 10
3
Deletion of glycoproteins gI and gE of FHV-1 reducesTCID50 , 10
4 TCID50 , or 10
5 TCID50 of FHV-1CV. A seventh viral virulencegroup of five age-matched cats served as nonimmunized
controls. Immunized cats were observed daily and Clinical scores after subcutaneous administration of
FHV-1CV were uniformly low. Only mild clinical signsscored for clinical signs for 14 days postinoculation
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TABLE 1 TABLE 3
Parent Strain Selection Virus Neutralizing Antibody Titers after Vaccination
I. Subcutaneous administrationVirus
neutralization
Virus neutralization titerb,ctitera,b Average total
clinical scorec
21 days 42 daysInoculation 21 days
FHV-1 strain Dosea postvaccination postvaccinationgroup n Dose postvaccination Postchallenged
FHVb-galgIgED 107TCID50 4 { 0.7 5 { 0.9FHV-1MSU 6 104 TCID50 6 { 0.99 37.67 { 5.35 (14)
FHV-1SA 107 TCID50 5 { 0.7 5 { 0.5FHV-1SA 6 104 TCID50 6 { 0.72 23 { 7.87 (21)
FHV-1CV 107 TCID50 4 { 0.7 5 { 0.5CNTRL 3 — 2 0
II. Oronasal administrationa Virus neutralization titers are given as the integer log2 , group mean
value for the reciprocal of the highest twofold dilution of immune serum Virus neutralization titerb,c
from each cat within the group that neutralized 100 TCID50 . The stan-
dard deviation is given as a measure of dispersion, if appropriate. Post-1stb Prevaccination titer for all cats was 2. vaccination 21 Prechallengec Average total clinical score is the average clinical score determined FHV-1 strain Dosed days 43 days
as previously described and is shown with the standard deviation and
range in parentheses (Sussman et al., 1995). FHV-1CV 103 TCID50 3 { 0.8 NDed Animals were observed for 14 days. FHV-1CV 104 TCID50 3 { 0.8 ND
FHV-1CV 105 TCID50 3 { 0.8 ND
FHVb-galgIgED 103 TCID50 2 2were observed following subcutaneous inoculation con-
FHVb-galgIgED 104 TCID50 2 2sisting of mild pyrexia in one cat and serous ocular dis- FHVb-galgIgED 105 TCID50 2 2
charge in one cat. The average clinical score for this
a Administered on Days 0 and 21.group was 0.40 { 0.55 with a range of 1.
b Virus neutralization titers are given as the integer log2 group meanIn contrast, oronasal administration of the FHV-1CV
value for the reciprocal of the highest twofold dilution of immune serumand FHVb-galgIgED FHV-1 strains revealed the high vir-
from each cat within the group that neutralized 100 TCID50 . The stan-ulence of FHV-1CV with respect to FHVb-galgIgED (Ta- dard deviation is given as a measure of dispersion, if appropriate.
ble 2). Cats administered the FHV-1CV strain by the oro- c Prevaccination titer for all cats was 2.
d Administered on Day 0.nasal route were afflicted with the same severe and per-
e ND, not determined.sistent clinical signs typically associated with a high-
dose acute infection of virulent FHV-1, such as FHV-1SA.
All FHV-1CV-inoculated cats presented with sneezing,
increasing FHV-1CV dose. Only mild clinical signs were
serous or mucopurulent nasal and ocular discharge,
observed in cats receiving FHVb-galgIgED by the orona-
open mouth breathing, coughing, anorexia, and dehydra-
sal route of administration. Since gI and gE were the
tion, regardless of the dose given. Severity of clinical
only genes deleted from FHV-1SA in the construction
signs and total clinical scores tended to increase with
of FHVb-galgIgED, these genes appear to be important
factors in the virulence of FHV-1.
TABLE 2
The effects of gI–gE on FHV-1-induced clinical signsOronasal Safety and Efficacy
Responses of nonvaccinated controls. Prior to chal-
Average Clinical scorea
lenge with the virulent strain FVR-SGE, all cats were clini-
cally healthy and not shedding either FHV-1 or felineVaccination Group n Postvaccinationb Postchallengeb
calicivirus. Clinical responses of unvaccinated control
FHV-1CV (103 TCID50)/ON 5 19.8 { 7.9 (19) ND cats exposed to 106 TCID50 of virulent challenge virus
FHV-1CV (104 TCID50)/ON 5 23.2 { 10.8 (27) ND have been previously described (Sussman et al., 1995).
FHV-1CV (105 TCID50)/ON 5 23.4 { 7.5 (19) ND Cats vaccinated oronasally were challenged oronasallyFHVb-galgIgED (103)/ON 5 0.8 { 1.3 (3) 5.2 { 4.2 (10)
with 105 TCID50 of FVR-SGE, a challenge dose prescribedFHVb-galgIgED (104)/ON 4 2.0 { 2.4 (6) 3.0 { 2.5 (6)
FHVb-galgIgED (105)/ON 5 3.2 { 2.17 (6) 1.60 { 2.0 (5) by the USDA for evaluation of FHV-1 vaccines and master
CNTRL 5 ND 21.4 { 7.5 (16) seed strains (U.S. Dept. of Agriculture, 1985). Clinical
responses of unvaccinated control cats exposed to 105a Average total clinical score is the average clinical score determined
TCID50 of virulent challenge virus are shown in Tables 2as previously described for all cats and is shown with the standard
and 3 and Figs. 2 and 3. Consistent with previous re-deviation and range in parentheses (Sussman et al., 1995).
b Animals were observed for 14 days. search describing the dose responsiveness of cats to
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virulent FHV-1, overall total clinical scores after challenge shown) were reduced in oronasal FHVb-galgIgED vac-
cinees compared to those in subcutaneous FHVb-gal-for the unvaccinated controls in the oronasal experiment
were smaller than those in the subcutaneous experiment gIgED vaccinees.
(Gaskell and Povey, 1979a).
Responses of subcutaneous vaccinees. Subcutaneous DISCUSSION
vaccination with FHV-1CV was effective in nearly elimi-
nating clinical signs due to virulent challenge in most Recently we described the construction of an FHV-1
recombinant strain (FHVb-galgIgED) with a deletion incats tested. The average clinical score for this group was
1.80{ 4.02 with a range of 9. Postchallenge clinical signs the genes that encode glycoproteins gI and gE. FHVb-
galgIgED does not produce the gE protein, nor an intactobserved in cats vaccinated with FHV-1CV included mild
pyrexia, transient sneezing, and serous ocular discharge. gI protein (Sussman et al., 1995). The parent strain for
FHVb-galgIgED is FHV-1SA. When administered orona-FHV-1CV or FHV-1SA (Sussman et al., 1995) was more
effective than FHVb-galgIgED in reducing clinical signs sally, even at a moderate dosage, FHV-1SA induces se-
vere clinical signs. Deletion of gI–gE from FHV-1SA sig-resulting from challenge. Although clinical signs were
similar to those observed in FHV-1SA and FHV-1CV vac- nificantly reduces the virulence of this strain based upon
a reduction in the overall clinical scores obtained fromcinees, the duration and severity of signs resulting from
challenge were greater in cats vaccinated with FHVb- cats that were given FHVb-galgIgED via the natural
route. Thus, glycoproteins gI and gE for FHV-1 are viru-galgIgED (Figs. 1 and 3).
Responses of oronasal vaccinees. In contrast to ad- lence genes in a natural host system. This is consistent
with the findings of other groups working with pseudora-ministration of FHVb-galgIgED via the subcutaneous
route, oronasal administration of FHVb-galgIgED com- bies virus and infectious bovine rhinotracheitis virus in
the natural host (Jacobs, 1994; Van Engelenburg et al.,pletely prevented all clinical signs resulting from virulent
challenge in two vaccinees. Other cats vaccinated orona- 1994).
As part of the safety evaluation of FHVb-galgIgED,sally with FHVb-galgIgED presented with only mild clini-
cal signs including sneezing, mild pyrexia, and serous we included another strain as a representative FHV-1
vaccine that has been licensed for use by the USDA.ocular discharge (Fig. 2). Mean total scores for clinical
signs tended to vary inversely with vaccine dose (Table The only prescribed route of vaccination for FHV-1CV is
subcutaneous. We have shown that administration of2). Postchallenge febrile responses were greatly reduced
in cats vaccinated oronasally with FHVb-galgIgED com- FHV-1CV via the oronasal route induces severe clinical
signs. In fact, FHV-1CV and FHV-1SA are both virulentpared to those in controls (Fig. 3).
FHV-1 strains. Therefore, administration of FHV-1CV by
Induction of virus neutralizing antibodies the unnatural subcutaneous route completely masks its
virulence. Since FHV-1CV could never be used as a vac-
We determined the virus neutralizing antibody titers
cine for FVR when administered oronasally, we did not
for each of the experimental cat groups after 21 days
continue with a virulent challenge for cats given this treat-
and either 42 or 43 days postvaccination. FHV-1 VN titers
ment.
following subcutaneous vaccination were moderate (Ta-
Oronasal administration of FHVb-galgIgED induces
ble 3). Mean antibody titers were not significantly differ-
strong immunity to virulent FHV-1 challenge. The dimin-
ent between the three groups of inoculated cats (one-
ished level of protection from virulent challenge induced
way ANOVA, P  0.07). Oronasal inoculation of FHV-1
by subcutaneous administration of the recombinant
induced lower VN titers, even in the case of FHV-1CV,
FHVb-galgIgED may be due to several factors. Two im-
which was highly virulent by the natural route (Table 3).
munogenic glycoproteins, gI and gE, were removed from
Mean antibody titers for cats receiving oronasal FHVb-
FHV-1 in FHVb-galgIgED. Consequently, cats only raise
galgIgED were significantly lower than those for the cor-
an immune response against the remaining glycopro-
responding oronasal FHV-1CV groups (paired t tests, P
teins. Thus, lack of a subset of circulating memory B- 0.003).
cells producing antibodies recognizing gI and gE may
influence complement-dependent and complement-inde-Reduction of postchallenge virus shedding
pendent virus neutralizing antibody levels. The intramus-
cular or subcutaneous route of administration is an un-Postchallenge virus shedding was substantially re-
duced in nearly all immunized cats compared to that in natural route of infection. Higher body temperatures hin-
der virus replication of all FHV-1 strains (Pedersen andcontrol cats. Among subcutaneously immunized cats,
cats receiving FHVb-galgIgED had a higher frequency Hawkins, 1995). The gI–gE mutation itself may hinder
virus replication somewhat more. Clinical signs inducedof virus shedding compared to that in FHV-1SA or FHV-
1CV vacinees (Fig. 1). However, duration of virus shed- by the parent strain were considered evidence of spread
of this strain to mucosae at the portals of entry whereding (Fig. 2) and magnitude of virus shedding (data not
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FIG. 1. Duration of clinical signs and shedding for subcutaneous efficacy. Gantt chart showing the time during which a clinical sign or shedding
persisted. The cat number is shown next to its respective bar. A bar is shown only if a clinical sign was observed or shedding occurred. Cats were
vaccinated as described under Materials and Methods and challenged with 106 TCID50 of FVR-SGE.
secondary replication can occur and secretory immunity lenge (Mestecky, 1987; Irie et al., 1992, 1993; Israel et
al., 1992).could be induced. In contrast, FHVb-galgIgED probably
did not spread from the point of subcutaneous inocula- We demonstrated that subcutaneous administration of
FHV-1 induced moderate VN titers, while VN titers fortion to the natural portals of entry (Sussman et al., 1995).
The greatest contribution to the total clinical score for oronasal administration of FHV-1 were low, except when
severe clinical signs were induced and virus apparentlythe FHVb-galgIgED cats was from pyrexia. Because fe-
ver is induced as a result of endogenous cytokine secre- spread beyond the surface epithelium. Parenteral inocu-
lation of FHV-1 induces the production of IgG and IgMtion by a diverse variety of cell types reacting to virus
invasion, it is likely that the stimulation for the febrile antibodies. These are likely to be the components con-
tributing to the VN titer that were measured.response arose from a rapid increase of virus particles
in the mucosal epithelial cells present at the portals of Neutralizing secretory antibody levels at the mucosal
surfaces of the natural portals of entry were not mea-entry (Kapas et al., 1995; Nagura et al., 1994). In the
case of FHV-1SA vaccination where virus shedding was sured in this study. However, the available data are sug-
gestive of a secretory immune response when cats aredetected from one cat (cat 274), and possibly FHV-1CV
vaccination, oronasal virus replication may have induced oronasally vaccinated or when a vaccine can travel to
the mucosal epithelial cells at the natural portals of entry.a secretory immune response, thus eliminating a cyto-
kine-dependent induction of a febrile response postchal- It was previously shown that such antibodies are present
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FIG. 2. Duration of clinical signs and shedding for oronasal efficacy. Gantt chart showing the time during which a clinical sign or shedding
persisted. The cat number is shown next to its respective bar. A bar is shown only if a clinical sign was observed or shedding occurred. Vaccination
groups: FHVb-galgIgED3, 103 TCID50 per cat; FHVb-galgIgED4, 104 TCID50 per cat; FHVb-galgIgED5, 105 TCID50 per cat.
at the portals of entry, but their neutralizing ability was sure to FHVb-galgIgED and is involved in protective im-
munity.not assessed (Cocker et al., 1986). The level of secretory
immunity at mucosal sites is probably related to the level Although the induction of secretory immunity is sug-
gested, a cell-mediated immune response may also beof local virus replication. Local virus replication directly
influences shedding. VN titers following subcutaneous involved. Indeed an FHV-1-specific immune response
can be induced in 2 days in naive cats, interferon isvaccination were moderate and there were no significant
differences between VN titers induced by any of the inoc- detected in both nasal washes and serum 6 days after
vaccination with a modified live FHV-1 vaccine, and pro-ulated strains. Yet, only subcutaneous FHV-1SA and
FHV-1CV were effective at eliminating clinical signs due liferation of lymphocytes as a result of FHV-1 infection
has been observed (Nasisse et al., 1995; Tham and Stud-to virulent challenge. Furthermore, oronasal inoculation
of FHV-1 induces a still lower VN titer, even in the case dert, 1987). Antibody-dependent and antibody-indepen-
dent cell-mediated cytotoxicity has been shown to beof FHV-1CV, which is highly virulent by the natural route.
Yet, in spite of an almost negligible VN titer, there is a involved in the clearance of FHV-1 at 6–8 hr postinfection
(Wardley, 1976). Thus, in addition to the humoral re-strong immune response against virulent challenge.
Thus, a component of the immune system that we have sponse, a fast specific immune mechanism acts upon
FHV-1 infection.not measured was induced as a result of oronasal expo-
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FIG. 3. FHV-1-induced fever for vaccine and challenge groups. Bars indicate the total number of days that all cats in a treatment group maintained
the rectal temperature listed in the key. (A) Subcutaneous route of administration (challenge, 106 TCID50 FVR-SGE). (B) Oronasal route of administration
(challenge, 105 TCID50 FVR-SGE). Cat groups are listed in Table 2 and Sussman et al. (1995).
Virus shedding after virulent virus challenge was re- significance in terms of companion animal health and
the generation of a safe and effective vaccine for FVR.duced significantly in FHVb-galgIgED vaccinees. The
magnitude and duration of virus shedding after chal-
lenge determine the amount of virulent virus in the ACKNOWLEDGMENTS
environment and may also have a correlation with la-
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